Strongbridge Biopharma plc Announces Acquisition of U.S. Rights to KEVEYIS® From Taro
December 23, 2016 08:01 ET
|
Strongbridge Biopharma plc
~ KEVEYIS is the First and Only FDA-Approved Treatment for Hyperkalemic, Hypokalemic, and Related Variants of Primary Periodic Paralysis, an Ultra-Orphan, Genetic Neuromuscular Disease ~ ~ KEVEYIS is...
$1.5 million gift to The Jackson Laboratory establishes Sims Family Fund for SMARD Research
August 05, 2015 16:08 ET
|
The Jackson Laboratory
BAR HARBOR, Maine, Aug. 5, 2015 (GLOBE NEWSWIRE) -- A $1.5 million gift to The Jackson Laboratory (JAX) from Mr. Grant Sims and Ms. Patricia (Patty) Sims of Houston, Texas, will fund research in a...